Recombinant Human CD33 Protein，His

CD33 (Cluster of Differentiation 33) is a sialic acid-binding immunoglobulin-like lectin predominantly expressed on myeloid cells, including monocytes, macrophages, and dendritic cells. It plays a critical role in the regulation of immune responses and is implicated in the pathogenesis of various hematologic malignancies, particularly acute myeloid leukemia (AML). The expression of CD33 on the surface of leukemic cells has made it an appealing target for immunotherapeutic strategies, including the development of monoclonal antibodies and antibody-drug conjugates. Researchers have focused on the engineering of CD33 recombinant proteins to better understand its structural and functional properties, facilitating the discovery of novel therapies. Studies exploring CD33's role in myeloid differentiation and its interactions with sialic acids also provide insights into its potential as a therapeutic target. Given the urgent need for effective treatments for AML and other CD33-positive malignancies, the development of CD33-targeted therapies through recombinant protein technology holds significant promise, paving the way for innovative approaches in cancer treatment and enhancing the body's immune response against tumor cells. Furthermore, understanding the molecular mechanisms by which CD33 influences immune modulation could lead to breakthroughs in enhancing the efficacy of existing therapies and addressing resistance mechanisms in malignancies.